The development of an effective intranasal vaccine has numerous potential advantages over conventional subcutaneous or intramuscular administration. First, the nasal passage is often the first point of entry for respiratory pathogens, and if the pathogen can be stopped in the nasal passages, the spread of infection is likely to be significantly reduced, which will improve prognosis.
Furthermore, direct immunization of the nasal mucosa can promote both mucosal and systemic immunity. Mucosal immunity may be key to preventing viral shedding and disease transmission.
In addition, self-administration of a “needle-free” vaccine provides painless administration to the patient, results in less medical waste by avoiding disposal of syringes, eliminates the requirement for extreme cold storage from the supply chain, and simplifies global distribution. . These aspects of nasal delivery could expand vaccine availability to larger populations in regions and countries with limited refrigeration infrastructure.
During the Vaccine Summit-2022, which took place on October 11-13, 2022 in Washington DC, USA, Aptar Pharma presented the research results of its collaboration with TFF Pharmaceuticals. The presentation highlighted data related to the nasal deposition of a dry powder vaccine, the physical characteristics of the administered formulation, the integrity and potency tests of the dry powder vaccine after administration, and the size of the particles emitted. The amount of dry powder delivered to the target region of the nasal cavity was also presented. Aptar Pharma will present additional data on these efforts at the World Congress on Vaccines and Immunotherapy, taking place in San Diego, CA, from November 28 to December 1, 2022.
“We are very excited to partner with Aptar Pharma to trial our thin-film freezing formulation with their unique intranasal device,” said Glenn Mattes, President and CEO of TFF Pharmaceuticals. “By combining our collective and proprietary expertise in drug development, device engineering, and formulation technologies, we believe this collaboration has the potential to create groundbreaking advances in the field of drug delivery. Intranasal dry powder vaccines could be a real game changer for people around the world.”
“The nasal vaccine formulation developed using TFF Pharmaceutical technology combines the antigen and adjuvant in a ready-to-use device,” said Dr. Julie D. Suman, Vice President of Scientific Affairs for Aptar Pharma. “This eliminates the need to combine separate vials, saves time, reduces human error and medical waste.”
Aptar Pharma, the University of Texas at Austin (UT), and TFF Pharmaceuticals will publish the results of the feasibility tests in the coming months. Aptar, UT and TFF are preparing to summarize the results of initial feasibility testing of the intranasal vaccine in a preprint publication to be followed by a peer-reviewed publication in the coming months.